How will the FTC lawsuit and privacy allegations affect Hims & Hers Health?
Hims & Hers Health faces legal and financial pressure from FTC lawsuit The Federal Trade Commission filed a lawsuit against Hims & Hers Health on July 29, 2026, alleging the company shared consumers' sensitive health information with third-party advertisers like Meta and Snap Inc. The complaint also claims Hims & Hers misled users by failing to clearly disclose that they are charged for prescriptions almost immediately after submitting an intake form. Following the news, Hims & Hers Health's stock price fell $4.32 per share, or 14.73%, to close at $25.00 on that day.
- Effect
- Strong negative
- How direct
- Stated in the reporting
- When
- Right away
- The story
- Gone quiet
How it reaches Hims & Hers Health
-
The Federal Trade Commission sued Hims & Hers regarding consumer protection issues, alleging the company engaged in deceptive advertising practices and shared sensitive user information with third parties. The FTC complaint alleges that Hims & Hers shared consumers' private health information about medical conditions with third-party advertising platforms. Furthermore, the company faced a class action lawsuit from investors regarding alleged undisclosed business practices during the class period.
The full event6independent outlets -
The FTC complaint alleges that Hims & Hers shared sensitive health information with third-party advertising platforms, including Meta Platforms, Inc. and Snap Inc., despite promising patient privacy. Additionally, the FTC alleges the company fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form.
4 reports connect these two. Brind only summarizes; follow a link to read the reporting itself.
- gazettextra.com Sep 25
- pr-inside.com Sep 19
- prnewswire.com Sep 15
- empr.com Aug 3
-
American telehealth company
Everything about Hims & Hers Health
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The FTC filed a lawsuit against Hims & Hers on July 29, 2026.gazettextra.com, pr-inside.com, prnewswire.com, empr.com
- Hims & Hers' stock fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026.gazettextra.com, pr-inside.com, prnewswire.com
- The FTC alleges Hims & Hers shared sensitive health information with Meta Platforms, Inc. and Snap Inc.gazettextra.com, pr-inside.com, prnewswire.com, empr.com
- A class action suit was filed on behalf of investors who acquired Hims & Hers securities between August 4, 2025 and July 29, 2026.gazettextra.com, prnewswire.com
Why it matters
Hims & Hers Health's business model relies heavily on collecting and managing sensitive health information to drive its high-growth, data-rich telehealth platform. Regulatory action from the FTC could force the company to change how it uses health data for targeting or upsell, which would directly impact its ability to generate recurring revenue and maintain earnings stability.
This legal pressure comes while the company is already navigating broader financial challenges, including an operating loss totaling $31 million over the trailing 12 months and volatile growth rates. The lawsuit reinforces the existing risk that Hims & Hers may face higher regulatory scrutiny compared to its peers.
What we don't know yet
- What specific remedies or penalties will the FTC seek in its lawsuit?
- How will the company adjust its data practices if court or FTC oversight mandates changes?
Is this still moving?
- Reports
- 18
- Developments
- 9
- Repetition
- 67%
What would change this answer
— Other considerations
Beyond this explainer
Explore connected ideas
Each opens a map of what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Reporting
- gazettextra.comSep 25
- pr-inside.comSep 19
- prnewswire.comSep 15
- empr.comAug 3
- yahoo.comAug 18
- fool.comAug 3
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. It is not investment advice; do your own research.